Wegovy and Mounjaro promise quick weight loss. But current long-term data shows: the price is high. In addition to the dreaded yo-yo effect, doctors are now warning of irreversible eye damage and massive muscle loss.
Almost three years after the global hype surrounding GLP-1 agonists, the euphoria has given way to a sober reality. The medication works – no question about it. But what does this weight loss really mean for the body? Current analyzes paint a more complex picture than the initial success stories on social media suggested.
The biggest problem: Patients don’t just lose fat. New evaluations of clinical studies show that between 25 and 40 percent of weight loss consists of muscle mass – significantly more than with conventional diets.
This pharmacologically induced muscle loss is particularly critical for people over 50. Doctors warn of accelerated sarcopenia, which leads to frailty, increased risk of falls and slowed metabolism.
Advertisement
From the age of 50, the body breaks down muscle more quickly – studies show that pharmacologically induced weight loss often also costs muscle mass. A simple 6-exercise plan helps to stop precisely this loss of strength: short, safe exercises to do at home, without equipment, with variations for beginners, and explains how to compensate for muscle loss after diet or drug therapy. Free PDF with exercise descriptions and weekly plan via email. Get free strength training for those over 50
“We see patients who are lighter on the scales, but functionally weaker,” report sports medicine experts. The phenomenon now has its own name: “Ozempic Body” – loose skin and lack of muscle tone due to rapid fat and tissue loss.
The recommendation is clear: no prescription without accompanying strength training and increased protein intake.
Harvard study: sevenfold increased risk of eye infarction
Table of Contents
A large-scale investigation by Harvard Medical School alarmed experts. The in JAMA Ophthalmology Published study identified a link between semaglutide and NAION – a rare form of ocular infarction.
The numbers are clear:
- Diabetic: Fourfold increased risk
- Obesity patients: More than seven times increased risk
NAION causes sudden, painless loss of vision in one eye – usually irreversible. Although the absolute number of those affected remains small, for ophthalmologists the signal is too strong to ignore.
Patients with known eye problems or circulatory problems should be particularly careful. Novo Nordisk emphasizes that causalities need to be further researched. But the educational discussions have already changed.
The guaranteed yo-yo effect
The most sobering finding concerns stopping the medication. The belief in a “cure” has proven to be an illusion. As soon as the active ingredient leaves the body, hunger returns with full force.
The numbers speak for themselves: patients take on average within a year two-thirds of the weight they lost again. Since muscle buildup occurs much more slowly than fat gain, body composition often deteriorates.
The result: The body fat percentage is often higher at the end than before the treatment – even if the weight is the same.
From treatment to long-term medication
These findings lead to a reassessment of therapy. Obesity is increasingly being treated as a chronic disease that may be permanent lifelong medication requires.
This raises massive questions: Who should pay for this? Statutory health insurance companies usually do not cover the costs of pure weight loss. Self-payers have to raise 300 to 500 euros per month.
Critics also complain that the medications are often prescribed without the necessary accompanying program. Online prescription platforms are flourishing, making it difficult for doctors to monitor the risks.
Tirzepatide overtakes semaglutide
The balance of power in the competition between active ingredients has shifted. Tirzepatide (Mounjaro/Zepbound) shows superior effectiveness in direct comparison studies:
- Semaglutide: Average 15% weight loss
- Tirzepatid: 20 to 25% weight loss
These results approximate bariatric surgery. However, both active ingredients share similar side effects: nausea, vomiting and the risk of stomach paralysis remain the most common reasons for discontinuation.
Two-class medicine for obesity
The medical landscape has fundamentally changed. The initial delivery bottlenecks have eased, but the cost issue remains unresolved.
The result is a two-tier medicine in obesity treatment. Only those who can afford it have access to pharmacological therapy. And even then the question remains: Is living with an injection really the solution?
The next generation is approaching
The pharmaceutical industry is already working on alternatives. Oral variants and “triple agonists” such as retatruide are in advanced phases of study. These are intended to actively increase calorie consumption and protect muscle mass better.
Experts expect a shift in focus: away from maximum weight loss and towards qualitative weight loss. In the future, medications will reduce fat but protect muscles.
Until then, the diet injection remains a powerful tool – but by no means harmless. Anyone who decides to do this should be aware that it could be a lifelong commitment.
Advertisement
PS: Many patients lose weight but become functionally weaker – this is exactly where a compact training plan comes in. The 6 exercise plan for at home shows how you can build muscle, reduce the risk of falls and regain your everyday strength in just a few minutes every day. Free PDF with step-by-step instructions and adjustments for different fitness levels – direct as an email download. Request a free 6 exercise plan now
